Clinical Trials
Smarter Resource Planning for Complex Pharma Development Portfolios
Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.
Business & Industry
Modernizing Governance Structures for Faster Portfolio Decisions
Accelerate pharmaceutical R&D decision-making by implementing modern governance frameworks that establish clear decision rights, defined escalation pathways and cross-functional ownership while maintaining strategic alignment and rigor.
Business & Industry
Aligning Scientific Innovation with Commercial Reality in Drug Development
The "Valley of Death" in pharma is no longer just about scientific failure; it is about commercial irrelevance. This article examines the critical need to align R&D ambition with market reality early in development. It explores the evolution of the Target Product Profile (TPP) into the Target Value Profile (TVP), the role of the "commercial scientist," and strategies for integrated evidence generation that satisfy both regulators and payers.
Business & Industry
How Advanced Analytics is Redefining Pharma Project Prioritization
The era of "gut feeling" in pharmaceutical portfolio management is ending. This article explores how advanced analytics, machine learning, and predictive modeling are revolutionizing project prioritization. It details the shift to Monte Carlo simulations, integrated data lakes, and AI-driven decision support, enabling companies to objectively rank programs and optimize R&D return on investment.
Business & Industry
Rethinking Pipeline Value Beyond Peak Sales Forecasts
The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.
Business & Industry
Building Resilient Pharma Portfolios in an Era of Scientific and Market Uncertainty
Pharmaceutical companies are radically redesigning portfolio strategies to survive a "triple threat" environment of scientific complexity, regulatory upheaval like the IRA, and capital scarcity. This analysis explores the shift from efficiency-driven models to resilience-first frameworks, detailing how leaders are embedding optionality into pipelines, embracing modality agnosticism, and using dynamic resource allocation to thrive amidst volatility.
BioPharma
Enhancing Lab Efficiency Through Cloud-Based Quality Systems
The manual control of laboratory quality may be a very difficult task to do, especially when considering the complexity of laboratory activities. Automating processes, providing visibility and traceability, assisting with risk management and change control, ensuring compliance, and providing...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















